December 27, 2023- Acute Respiratory Distress Syndrome (ARDS) is a life-threatening lung condition with causes, including severe pneumonia and sepsis, leading to high death rates among hospital patients. There are currently no approved therapies or treatments for ARDS. Thermo Fisher Scientific has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate therapeutic options for the treatment of ARDS.
The primary objective of the BARDA-funded, hypothesis-generating study is to gather comprehensive clinical and biomarker data on the ARDS patient population to better inform future clinical studies and contribute to the development of targeted therapies for ARDS.